MedTrace Logo

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

NCT02367638 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-04-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.

Conditions

  • Varicella (Chicken Pox)

Interventions

BIOLOGICAL

MG1111

Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection

BIOLOGICAL

VARIVAX

VARIVAX is administered by subcutaneous injection

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02367638 on ClinicalTrials.gov